Literature DB >> 4280523

Suppression by the spironolactone metabolite canrenone of plasma testosterone in man.

H C Erbler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4280523     DOI: 10.1007/bf00501468

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  5 in total

1.  A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy.

Authors:  J E Castro; H J Griffiths; D E Edwards
Journal:  Br J Surg       Date:  1971-07       Impact factor: 6.939

2.  Antiandrogenic effect of spironolactone in rats.

Authors:  G T Basinger; R F Gittes
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

3.  Anti-androgenic activity of spironolactone.

Authors:  S L Steelman; J R Brooks; E R Morgan; D J Patanelli
Journal:  Steroids       Date:  1969-10       Impact factor: 2.668

4.  Aldosteronism in hypertension. The spironolactone response test.

Authors:  R F Spark; J C Melby
Journal:  Ann Intern Med       Date:  1968-10       Impact factor: 25.391

5.  Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin.

Authors:  J J Brown; D L Davies; J B Ferriss; R Fraser; E Haywood; A F Lever; J I Robertson
Journal:  Br Med J       Date:  1972-06-24
  5 in total
  3 in total

1.  Canrenoate disposition in dogs. Tissue distribution and elimination.

Authors:  J Kuhlmann; V Kötter; N Rietbrock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-06       Impact factor: 3.000

2.  Effects of repeated administration of potassium canrenoate (SC-14266) on serum gonadotrophin, prolactin, testosterone and progesterone in male rats.

Authors:  T Muraki; T Nakadate; K Kubota; Y Tokunaga; R Kato
Journal:  Experientia       Date:  1980-06-15

3.  Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy.

Authors:  Lachlan Angus; Shalem Leemaqz; Olivia Ooi; Pauline Cundill; Nicholas Silberstein; Peter Locke; Jeffrey D Zajac; Ada S Cheung
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.